Akebia Therapeutics(AKBA)
CAMBRIDGE, MABiotechnology
Focus: Akebia Therapeutics is a public biotechnology company focused on small-molecule therapeutics for hematology, nephrology, respiratory, metabolic, and cardiovascular diseases. The company generates ~$195M in annual revenue with one marketed product (VAFSEO/vadadustat) and a pipeline spanning early- to late-stage development.
Profile data last refreshed 17h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Akebia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Akebia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Akebia Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$195M
Key Products
GROWTH9.5yr
Akebia's sole marketed product and HIF-PHI hypoxia-inducible factor prolyl hydroxylase inhibitor; VOICE trial demonstrated safer composite outcomes vs. erythropoiesis-stimulating agents (ESA) as of June 2026.
Help build intelligence for Akebia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.